HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nov. 14, 2005--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2005. Product sales increased by 31% for the first nine months of 2005 compared to the same period in 2004. Product sales for the first nine months of 2005 amounted to $318,424, compared to $243,579 for the same period in 2004. Nymox reported a net loss of $958,464, or $0.04 per share, for the quarter compared to $695,031, or $0.03 per share, for the same period in 2004, and $2,763,440, or $0.11 per share, for the nine months ended September 30, 2005, compared to $2,801,353, or $0.11 per share, for the nine months ended September 30, 2004. Nymox currently has $13 million in financing available from its most recent October 21, 2005 financing. The weighted, diluted average number of common shares at September 30, 2005 was 25,936,032, compared to 25,013,214 at September 30, 2004.
